 CAMBRIDGE, Mass. and NEW YORK, March 02, 2021 GLOBE NEWSWIRE -- Black Diamond Therapeutics, Inc. Nasdaq: BDTX, a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data from two programs emerging from the Companys proprietary MAP platform targeting BRAF and fibroblast growth factor receptor FGFR at the European Society of Medical Oncology Targeted Anticancer Therapies ESMO TAT Virtual Congress 2021, taking place March 1-2, 2021. 